FOR IMMEDIATE RELEASE
MS Society announces $2.4 million
to continue Ottawa
bone marrow stem cell transplant trial
July 17, 2007 – The Multiple Sclerosis Society of Canada announced
a $2.4 million grant to continue a closely-watched clinical trial involving
an experimental bone marrow stem cell transplant therapy. The trial is
being conducted by a team of Canadian MS specialists led by Dr. Mark Freedman
and Dr. Harry Atkins in Ottawa.
“The aim of the study was to see if this treatment protocol could
halt deterioration in a group of MS patients with rapidly progressive
disease,” says Jon Temme, vice president of client services and
research for the MS Society. “Currently, the majority of the 18
patients have stabilized or improved, and the focus of this second phase
of the trial will be to determine if this stabilization can be maintained.”
Multiple sclerosis is a chronic, often disabling disease of the brain
and spinal cord. Between 55,000 and 75,000 Canadians have MS making it
the most common neurological disease of young adults in Canada. Most people
with MS are diagnosed between the ages of 15 and 40.
MS symptoms are unpredictable and vary greatly from person to person
but can include: double or blurred vision; extreme fatigue; loss of balance;
stiffness of muscles; speech problems; bladder and bowel problems; and
even partial or complete paralysis.
“The idea behind this clinical trial is to replace the diseased
immune system with a new one derived from the patient’s own bone
marrow stem cells,” explains Dr. Harry Atkins, a scientist at the
Ottawa Health Research Institute, bone marrow transplant specialist at
the Ottawa Hospital, and assistant professor at the University of Ottawa. “First
we purify and freeze the patient’s stem cells, then we use strong
chemotherapy to destroy their existing immune system, and then we transplant
the purified stem cells back into the patient. It takes time, but eventually
these stem cells will form a completely new immune system – one
that does not attack the brain and spinal cord – we hope.”
A similar procedure has been used to treat certain types of blood cancer
for more than 25 years, but applying the procedure to treat autoimmune
diseases such as MS is novel.
“We hoped that this therapy would halt or slow the progression
of MS, and in the patients examined so far, it seems to have worked,” says
Dr. Mark Freedman, a senior scientist at the Ottawa Health Research Institute,
director of the Ottawa Hospital MS Clinic, and professor at the University
of Ottawa. “In addition, some patients have experienced substantial
improvements in their ability to see and walk. This was unexpected, and
it suggests the exciting possibility that the therapy may be contributing
to some sort of repair or regeneration. With this funding, we can investigate
this further.”
The researchers note that the therapy is highly experimental and potential
side effects are serious, but the knowledge gained could lead to significant
improvements in the treatment of MS and other autoimmune diseases.
The grant to extend the project comes from the MS Scientific Research
Foundation which receives the majority of its funding from the MS Society
of Canada.
About the Ottawa Health Research Institute
The Ottawa Health Research Institute (OHRI) is the research
arm of The Ottawa Hospital and an affiliated institute of the
University of Ottawa. The OHRI includes more than 1,200 scientists,
clinicians, graduate students, postdoctoral fellows, and staff
conducting research to improve the understanding, prevention,
diagnosis and treatment of human disease. For more information,
visit www.ohri.ca.
About the MS Society of Canada
Founded in 1948, the MS Society has a membership of 28,000, with
seven regional divisions and nearly 120 chapters. The MS Society provides
services for people with MS, family members and caregivers. The MS Society
also offers a unique support network for children and teenagers with
MS and their parents. The MS Society raises funds to support research
and services almost entirely through individual and corporate donations
and fundraising events across the country. For more information, visit
www.mssociety.ca.
-30-
Media Contacts:
Jennifer Paterson
Ottawa Health Research Institute
613-798-5555, extension 19691
jpaterson@ohri.ca
Stewart Wong
MS Society of Canada
416-967-3025
stewart.wong@mssociety.ca
|
